USPTO Art Unit 1622 Prosecution Statistics

Art Unit Information

Art Unit: 1622
Group: 1620
Tech Center: 1600
Total Cases: 13,745
Last Active: January 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19018731PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERSJanuary 2025March 2025Allow200YesNo
18987568SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUNDDecember 2024June 2025Allow601YesNo
18988163SYNTHESIS OF KRAS G12C INHIBITOR COMPOUNDDecember 2024June 2025Abandon610NoNo
18988090SYNTHESIS OF KRAS G12C INHIBITOR COMPOUNDDecember 2024June 2025Abandon610NoNo
18985720DITHIENYL DISULFIRAM DERIVATIVES AS SELECTIVE ALDH1A1 INHIBITORSDecember 2024May 2025Allow510YesNo
18974530Preparation Method and Application of Micelle Preparation Containing Thymol and Derivative ThereofDecember 2024March 2025Allow300YesNo
18968074EMULSIFIABLE NEONICOTINOID PESTICIDE CONCENTRATEDecember 2024February 2025Allow300YesNo
18927346COMPOSITIONS OF THIENOPYRIMIDINE DERIVATIVESOctober 2024April 2025Allow611YesNo
18915221AZAINDOLE ROCK INHIBITORSOctober 2024January 2025Allow300NoNo
18913645PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOFOctober 2024April 2025Allow611NoNo
18905898METHOD OF TREATING HAIR LOSS DISORDERSOctober 2024March 2025Allow500YesNo
18895223METHOD OF TREATING CANCER IN A SUBJECTSeptember 2024March 2025Allow601YesNo
18882644QUINOLINONE AMIDE COMPOUNDS AND USES THEREOFSeptember 2024April 2025Allow811NoNo
18820199NAPHTHALENE ISOXAZOLINE COMPOUND AND APPLICATION THEREOFAugust 2024December 2024Allow400YesNo
18812527MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOFAugust 2024March 2025Allow711YesNo
18807584FORMULATIONS OF AMINOPENICILLIN AND METHODS FOR SOLUBILIZING AMINOPENICILLINAugust 2024May 2025Allow920YesNo
18805702Diagnosis and Treatment of VitiligoAugust 2024May 2025Allow911YesNo
18723881SALT FORM AND CRYSTAL FORM OF TETRAHYDROCYCLOHEPTA INDAZOLE COMPOUNDAugust 2024May 2025Allow1010YesNo
18794128AMLODIPINE FORMULATIONSAugust 2024April 2025Allow811NoNo
18792836METHODS OF TREATING BRAIN DISORDERSAugust 2024May 2025Allow911NoNo
18832280BENZOISOTHIAZOLE AND BENZOISOXAZOLE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERSJuly 2024February 2025Allow700YesNo
18776040PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOFJuly 2024January 2025Allow620NoNo
18764507SULFORAPHANE-CYSTEINE FOR WOUND HEALING IN DIABETIC SUBJECTSJuly 2024November 2024Allow400YesNo
18750014METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORSJune 2024March 2025Allow910NoNo
18750032METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORSJune 2024April 2025Allow1010NoNo
18743233PHARMACEUTICAL COMBINATIONS FOR TREATING CANCERJune 2024May 2025Allow1110NoNo
18744484NOVEL COMPOSITIONS OF MATTER AND PHARMACEUTICAL COMPOSITIONSJune 2024May 2025Allow1110NoNo
18743475SARS-COV2 MAIN PROTEASE INHIBITORSJune 2024April 2025Allow1110NoNo
18743025ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOFJune 2024March 2025Allow920NoNo
18734105PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOFJune 2024December 2024Allow611NoNo
18675584PIKfyve InhibitorsMay 2024June 2025Abandon1210NoNo
18674104MIRDAMETINIB TREATMENTMay 2024June 2025Abandon1210NoNo
18674233MIRDAMETINIB TREATMENTMay 2024September 2024Allow410YesNo
18674168MIRDAMETINIB TREATMENTMay 2024January 2025Allow810NoNo
18710989MELAMINE PROCESS WITH A TWO-STAGE PURIFICATION OF MELAMINE OFFGASMay 2024June 2025Allow1300NoNo
18660829THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS AND USES THEREOFMay 2024April 2025Allow1111NoNo
18652993RAMIPRIL SOLUTION FOR ORAL DOSAGEMay 2024May 2025Allow1221YesNo
18705067METHOD FOR OLEFIN HYDROFORMYLATION USING IRIDIUM-BASED CATALYSTApril 2024August 2024Allow400NoNo
18644728NOVEL LIPIDS AND NANOPARTICLE COMPOSITIONS THEREOFApril 2024January 2025Allow911YesNo
18635697EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL LUNG CANCERApril 2024May 2025Abandon1310NoNo
18629056METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESSApril 2024May 2025Allow1320YesNo
18626881REAGENTS FOR QUANTITATIVE MASS SPECTROMETRYApril 2024September 2024Allow511NoNo
18618311Pharmaceutical Compositions Having Improved Storage StabilityMarch 2024February 2025Allow1010NoNo
18614993COMPOSITIONS AND METHODS FOR TREATING HYPERTENSIONMarch 2024March 2025Abandon1220NoNo
18610051AZAINDOLE ROCK INHIBITORSMarch 2024January 2025Allow1010YesNo
18606994INJECTABLE GOLD-BASED PHARMACEUTICAL COMPOSITIONMarch 2024July 2024Allow501NoNo
18606165PHARMACEUTICAL COMPOSITION WITH PRIMARY AND SECONDARY THERAPEUTIC AGENTSMarch 2024July 2024Allow501NoNo
18604731N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDSMarch 2024June 2025Abandon1501YesNo
18601528COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONSMarch 2024October 2024Allow701NoNo
18600419NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENSMarch 2024April 2025Allow1310NoNo
18600431NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENSMarch 2024August 2024Allow610NoNo
18596586NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETYMarch 2024January 2025Allow1010NoNo
18591969CRYSTALLINE SALTS OF PSILOCINFebruary 2024March 2025Allow1201YesNo
18591925CRYSTALLINE SALTS OF PSILOCINFebruary 2024March 2025Allow1201YesNo
18590713POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINSFebruary 2024December 2024Allow1001YesNo
18590910ANALGESIC AND ANTIPRURITIC PHARMACERTICAL COMPOSITION AND APPLICATION THEREOFFebruary 2024February 2025Allow1100YesNo
18588626TOPICAL FORMULATION FOR A JAK INHIBITORFebruary 2024December 2024Allow1010YesNo
18685899ABIRATERONE PRECURSOR COMPOUND AND PREPARATION METHOD AND USE THEREOFFebruary 2024June 2025Allow1621YesNo
18584272VANADIUM ALKYLIDENE COMPLEX, SYNTHESIS AND USE THEREOFFebruary 2024September 2024Allow611NoNo
18582218IRAK DEGRADERS AND USES THEREOFFebruary 2024October 2024Allow800NoNo
18443509METALLOENZYME INHIBITOR COMPOUNDSFebruary 2024March 2025Allow1311NoNo
18441397STABLE PHARMACEUTICAL COMPOSITIONS OF CYCLOPHOSPHAMIDEFebruary 2024January 2025Abandon1110NoNo
18437335PRMT5 INHIBITORS AND METHODS OF USEFebruary 2024July 2024Allow500NoNo
18438077CHEMICAL COLLECTION AND PROCESSING VESSEL AND METHODS FOR FLUID TRANSFER AT SEAFebruary 2024April 2024Allow300NoNo
18682658METHOD FOR CATALYZING OLEFIN CARBONYLATIONFebruary 2024June 2024Allow400NoNo
18436569EMULSIFIABLE CONCENTRATE (EC) FORMULATION OF NITENPYRAMFebruary 2024November 2024Allow911YesNo
18433881THERAMUTEIN MODULATORSFebruary 2024October 2024Allow800NoNo
18430796COMPOSITIONS AND METHODS FOR TREATING ENDOCRINE DISEASES AND DISORDERSFebruary 2024August 2024Allow601NoNo
18430056C7 SUBSTITUTED OXYSTEROLS AND METHODS OF USE THEREOFFebruary 2024February 2025Allow1210YesNo
184254663-(2-(6-METHOXYPYRIDIN-3-YL)-4,5-DIPHENYL-1H-IMIDAZOL-1-YL)-N,N-DIMETHYLPROPAN-1-AMINE AS AN ANTICANCER COMPOUNDJanuary 2024June 2025Abandon1620NoNo
18422704DOSING OF KRAS INHIBITOR FOR TREATMENT OF CANCERSJanuary 2024June 2025Abandon1710NoNo
18420250METHOD OF TREATING ALZHEIMER�S DISEASEJanuary 2024October 2024Abandon910YesNo
18418030METHODS OF USE OF EMULSION FORMULATIONS OF AN NK-1 RECEPTOR ANTAGONISTJanuary 2024July 2024Allow610NoNo
184127586-AMINO-8,9-DI(4-METHOXYPHENYL)-2-OXO-3,9-DIHYDRO-2H-[1,3]THIAZOLO[5',4':5,6]PYRANO[2,3-B]PYRIDINE-7-CARBONITRILE AS ANTICANCER COMPOUNDJanuary 2024June 2025Abandon1720YesNo
18408486METHODS OF USE OF EMULSION FORMULATIONS OF AN NK-1 RECEPTOR ANTAGONISTJanuary 2024June 2024Allow510NoNo
18403960ENHANCED CONFECTIONERYJanuary 2024August 2024Allow710YesNo
18402996WATER SOLUBLE PLATINUM (II) AMINO ACID SCHIFF BASE AS AN ANTITUMOR DRUGJanuary 2024June 2024Allow500NoNo
18402678CHEMOSELECTIVE HYDROGENATION OF a,B-UNSATURATED KETONE AND POLYELECTROCHROMISM OF ELECTRONICALLY WEAKLY COUPLED 4,4'-DIVINYLAZOARYLENE-BRIDGED DIRUTHENIUM COMPLEX BEARING TWO Ru(CO)(2-HYDROXYQUINOLATO(PiPr3)2 MOIETIESJanuary 2024June 2024Allow500NoNo
18399457PREPARATION METHOD OF RESVERATROL NERVONIC ACID ESTERDecember 2023March 2024Allow200NoNo
18395738METHOD OF PREPARING CAMSYLATE SALTS OF TRIAZOLOPYRAZINE DERIVATIVESDecember 2023January 2025Allow1210NoNo
18395739METHOD OF INHIBITING KINASE BY CAMSYLATE SALTS OF TRIAZOLOPYRAZINE DERIVATIVESDecember 2023January 2025Allow1210YesNo
183947033-(2-(4-METHOXYPYRIDIN-3-YL)-4,5-DIPHENYL-1H-IMIDAZOL-1-YL)-N,N-DIMETHYLPROPAN-1-AMINE AS AN ANTI-CANCER COMPOUNDDecember 2023June 2025Abandon1720NoNo
18393778SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOFDecember 2023October 2024Allow1010NoNo
18392562REVERSIBLE PHOTOSWITCHABLE ISOMERIZATION OF NOVEL STERICALLY HINDERED 2,2',6,6'-TETRAMETHYL-4,4'-DIETHYNYLAZOBENZENEDecember 2023March 2024Allow310NoNo
18389711PSYCHOTROPIC AGENTS AND USES THEREOFDecember 2023April 2024Allow410NoNo
18539786PHOTOSWITCHABLE ISOMERIZATION OF NOVEL STERICALLY HINDERED 2,2',6,6'-TETRAISOPROPYL-4,4'-BIS((TRIMETHYLSILYL)ETHYNYL)AZOBENZENEDecember 2023April 2024Allow410NoNo
18538067JAK1 SELECTIVE INHIBITORSDecember 2023July 2025Allow1901NoNo
18530758AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORSDecember 2023December 2024Abandon1310NoNo
18529311PYRIDO[3',4':4,5]PYRROLO[3,2-C]NAPHTHYRIDINE COMPOUNDS AS CK2 INHIBITORSDecember 2023January 2025Allow1311NoNo
18529689TEAD INHIBITORS AND METHODS OF USES THEREOFDecember 2023April 2024Allow501YesNo
18528684STABLE PHARMACEUTICAL COMPOSITIONS OF SUCCINYLCHOLINE CHLORIDEDecember 2023August 2024Allow920YesNo
18526380Substituted 4-Benzyl And 4-Benzoyl Piperidine DerivatesDecember 2023June 2025Allow1810NoNo
18526408Spiropiperidine DerivativesDecember 2023June 2025Allow1810NoNo
18526030METHOD FOR IMPROVING THE SENSORIAL PROPERTIES OF OIL-IN-WATER EMULSIONS, TO REDUCE THE ADHESIVE EFFECT OF SUCH GLYCERIN-BASED OIL-IN-WATER EMULSIONSDecember 2023February 2025Allow1410YesNo
18519150SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITYNovember 2023April 2025Allow1611NoNo
18518127MIRDAMETINIB TREATMENTNovember 2023May 2025Allow1711NoNo
18513888CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS RELAPSED/REFRACTORY TO PRIOR TREATMENTNovember 2023February 2025Allow1501NoNo
185105947-IMINO-5-(1H-INDOL-3-YL)-1,3-SUBSTITUTED-7,8-DIHDROPYRIMIDO[4,5-D]PYRIMIDINE-2,4(1H,3H)-DIONE AS ANTI-INFLAMMATORY AGENTSNovember 2023July 2024Allow811NoNo
183891461,4-DIVINYLPHENYLENE-BRIDGED DIRUTHENIUM COMPLEX BEARING TWO RU(CO)(2-MERCAPTOQUINOLATO)(PIPR3)2 MOIETIES AS AN ORGANIC CATALYSTNovember 2023March 2024Allow410NoNo
183887321-(BUTYL(2-HYDROXY-3-(NAPHTHALEN-1-YLOXY)PROPYL)AMINO)-3-(NAPHTHALEN-2-YLOXY)PROPAN-2-OL AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)November 2023January 2024Allow200NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1622.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
41
Examiner Affirmed
17
(41.5%)
Examiner Reversed
24
(58.5%)
Reversal Percentile
95.8%
Higher than average

What This Means

With a 58.5% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
390
Allowed After Appeal Filing
154
(39.5%)
Not Allowed After Appeal Filing
236
(60.5%)
Filing Benefit Percentile
83.2%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 39.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Art Unit 1622 - Prosecution Statistics Summary

Executive Summary

Art Unit 1622 is part of Group 1620 in Technology Center 1600. This art unit has examined 13,745 patent applications in our dataset, with an overall allowance rate of 80.0%. Applications typically reach final disposition in approximately 22 months.

Comparative Analysis

Art Unit 1622's allowance rate of 80.0% places it in the 58% percentile among all USPTO art units. This art unit has an above-average allowance rate compared to other art units.

Prosecution Patterns

Applications in Art Unit 1622 receive an average of 1.27 office actions before reaching final disposition (in the 11% percentile). The median prosecution time is 22 months (in the 86% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more favorable examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is shorter than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.